201809-22-5

Basic information

• Product Name: 4-(5-CARBOXY-PYRIDIN-2-YL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 6-[4-(tert-Butoxycarbonyl)piperazin-1-yl]nicotinicacid97%;4-(5-CARBOXY-PYRIDIN-2-YL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;6-[4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL]NICOTINIC ACID;6-[4-(PIPERAZIN-1-YL)]NICOTINIC ACID, N4-BOC PROTECTED;6-Piperazin-1-ylnicotinic acid, N4-BOC protected;6-Piperazin-1-ylnicotinic acid, N4-BOC protected 97%;N4-BOC-6-PIPERAZIN-1-YLNICOTINIC ACID;6-[4-(tert-butoxycarbonyl)piperazino]nicotinic acid
• CAS NO: 201809-22-5
• Molecular Formula: C₁₅H₂₁N₃O₄
• Molecular Weight: 307.34
• Mol File: 201809-22-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 298 °C
• Boiling Point: 497.4 °C at 760 mmHg
• Flash Point: 254.6 °C
• Appearance: /
• Density: 1.25 g/cm³
• Refractive Index: 1.507
• Storage Temp.: 2-8°C
• PKA: 3.12±0.10(Predicted)
• CAS DataBase Reference: 4-(5-CARBOXY-PYRIDIN-2-YL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-CARBOXY-PYRIDIN-2-YL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(201809-22-5)
• EPA Substance Registry System: 4-(5-CARBOXY-PYRIDIN-2-YL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(201809-22-5)

Safety Data

• Statements: 20/21/22
• Safety Statements: 24/25-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 201809-22-5(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C16H28N2O5Si/c1-10-8-18(15(21)17-14(10)20)13-7-11(19)12(23-13)9-22-24(5,6)16(2,3)4/h8,11-13,19H,7,9H2,1-6H3,(H,17,20,21)/t11-,12-,13+/m1/s1

Upstream product

• 201809-20-3 tert-butyl 4-(5-(ethoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 1427-06-1 methyl 6-fluoropyridine-3-carboxylate 
• 857284-21-0 tert-butyl 4-(5-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate 

Downstream Products

• 936755-57-6 tert-butyl 4-(5-{[(4-nitro-1-phenyl-1H-pyrazol-3-yl)amino]carbonyl}pyridin-2-yl)piperazine-1-carboxylate 
• 1035269-57-8 N-[5-[(3,5-dimethoxyphenyl)methoxy]-2H-pyrazol-3-yl]-6-piperazin-1-yl-pyridine-3-carboxamide 
• 1354355-43-3 tert-butyl 4-(5-((3-fluoro-4-(2-methylpyridin-4-yl)benzyl)carbamoyl)pyridin-2-yl)piperazine-1-carboxylate 
• 1354355-45-5 N-(3-fluoro-4-(2-methylpyridin-4-yl)benzyl)-6-(piperazin-1-yl)nicotinamide 
• 1354353-63-1 6-(4-acetylpiperazin-1-yl)-N-(3-fluoro-4-(2-methylpyridin-4-yl)benzyl)nicotinamide 
• 1374892-58-6 {(S)-2-Methyl-1-[(S)-2-(4-{4'-[(6-piperazin-1-yl-pyridine-3-carbonyl)-amino]-biphenyl-4-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester 

Relevant articles and documents

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.